136 Lyme borreliosis David Banach and Gopi Patel Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports (Courtesy of Daniel Caplivski MD. Mount Sinai School of Medicine, New York, NY.) Lyme disease is a multisystem illness caused by spirochetes of the genus Borrelia. In North America, the causative agent is Borrelia burgdorferi. In Europe, borreliosis is caused primarily by B. afzelii followed by B. garni although other Borrelia species have been implicated. Clinical manifestations of Lyme disease depend on the stage of illness and may be limited to the skin or involve the nervous system, joints, or heart. Currently, Lyme disease is the most common vector-borne disease in the US. It is endemic in the northeast, the mid-Atlantic, and parts of Wisconsin and Minnesota. The most common vector for Lyme disease in the US is the Ixodes scapularis tick. I. pacificus has been linked to transmission of B. burgdorferi in the northwestern US. Mice and deer are the major reservoirs of B. burgdorferi. Ixodes ticks feed once in each of the three stages of their two-year life cycle. After hatching in the spring, larvae feed in summer, acquiring B. burgdorferi from their preferred host, the white-footed mouse. The following spring, the larvae develop into nymphs, which again feed off the white-footed mouse. The nymphs mature into adult ticks, which feed and mate in autumn and winter, usually on the white-tailed deer. B. burgdorferi is passed between ticks and their hosts. Humans can become accidental hosts during the spring and summer, when nymphs are actively feeding, through the deposition of organisms into the skin through tick saliva. Management strategy Routine antimicrobial prophylaxis or serologic testing after a tick bite is not recommended. Some experts recommend prophylaxis for patients bitten by I. scapularis ticks that have been attached over 36 hours if exposure occurred in an endemic area. This recommendation is based on evidence that a single 200 mg dose of doxycycline prevented 87% of Lyme infections if administered within 72 hours of tick removal. Accurate and detailed exposure history, however, is often unavailable. Those with a known tick exposure should be monitored for up to 30 days for the occurrence of skin lesions or fever. Cutaneous lesions or symptoms developing within one month after tick removal should prompt evaluation for early Lyme disease. The best mode of preventing Lyme disease is avoidance of tick-infested areas. If tick exposure is unavoidable, then one should wear light-colored clothing and long pants tucked into socks to prevent ticks from finding exposed skin. Skin self-inspection within 36 hours of tick exposure and bathing within 2 hours of exposure have been associated with decreased risk of Lyme borelliosis. Daily inspection of the entire body, including the scalp, is recommended since attached ticks removed within 24–36 hours are unlikely to transmit B. burgdorferi. DEET-containing insect repellents provide added protection. Ixodes ticks are small: larvae are less than 1 mm in size and adult females are 2–3 mm in size. Attached ticks should be removed with tweezers by carefully pulling on the mouth apparatus close to the skin, taking care not to leave parts of the embedded tick behind. Lyme disease generally occurs in stages, with different signs and symptoms at each stage. Therapeutic recommendations vary depending on the stage of disease and the presence of extracutaneous manifestations. Early localized Lyme disease The most common clinical manifestation of early Lyme disease is erythema migrans (EM). This characteristic skin lesion usually begins as an erythematous papule and develops into an expanding, erythematous, annular lesion with central clearing and distinct edge at the site of the tick bite and can be minimally tender. In most patients with Lyme, EM appears a median of 10 days after spirochete inoculation. The lesion may be accompanied by non-specific symptoms including fever, regional lymphadenopathy, arthralgias, fatigue, and headaches. About 75–80% of patients in the US who present with EM have a single primary lesion. Others can have secondary lesions due to hematogenous dissemination from the primary site. Untreated lesions usually fade within three to four weeks. Administration of doxycycline 100 mg twice daily, amoxicillin 500 mg three times daily, or cefuroxime axetil 500 mg twice daily for at least 14 days is recommended for early localized or early disseminated Lyme disease associated with EM. Doxycycline has the advantage of treating human granulocytic anaplasmosis caused by Anaplasma phagocytophilium, which also can be transmitted by I. scapularis. Doxycycline can cause photosensitivity and is contraindicated during pregnancy or breastfeeding and for children less than eight years old. A rare skin manifestation of early Lyme infection described predominantly in Europe is Borrelial Lymphocytoma (BL). This solitary bluish-red nodule occurs at the site of a tick bite typically preceding or concomitantly with EM. Commonly involved sites are the ear lobes in children and near or on the nipple in adults. BL may develop within weeks to months after a tick bite and if untreated can persist for months to years. Treatment regimens used to treat EM can be used to treat BL. Early disseminated Lyme disease Early dissemination of the spirochete occurs via blood or lymphatics over several weeks in untreated infection. In this setting multiple annular skin lesions resembling primary EM can appear though these lesions are generally smaller. Other common symptoms include fever, lethargy, myalgias, headache, and mild neck stiffness. Patients may present with atrioventricular (AV) conduction disturbances, iritis or uveitis, aseptic meningitis (lymphocytic pleocytosis in CSF), cranial nerve palsies (notably facial nerve palsies), or peripheral radiculopathy. In adults, intravenous ceftriaxone 2 g daily for 14–28 days is recommended for early Lyme disease presenting with neurologic or advanced cardiac conduction abnormalities. Parenteral penicillin or cefotaxime are second-line agents. Temporary pacing may be required for patients with high-degree AV block (PR interval ≥ 0.30 seconds). Insertion of a permanent pacer is not necessary as conduction defects resolve spontaneously. Isolated facial nerve palsy and first degree AV block can be treated with oral doxycycline. Late Lyme disease Late Lyme disease can occur months to years after previously untreated or inadequately treated initial infection. Lyme arthritis is the most common manifestation of late Lyme disease, although decreasing in incidence due to improved recognition of early disease. Lyme arthritis is oligoarticular and presents as recurrent swelling of large joints, primarily the knees. Persistent swelling is atypical. Positive serologic testing is required to confirm the diagnosis and positive PCR results from synovial fluid strengthens the diagnosis. Late neuroborreliosis is rare and can manifest as peripheral neuropathy, encephalomyelitis, or a subacute encephalopathy characterized by memory disturbances, mood alterations, and somnolence. A rare dermatologic finding associated with late Lyme disease is acrodermatitis chronica atrophicans (ACA). ACA has been predominantly described in elderly female patients and has rarely been seen in the US, but is not infrequent in Europe due to its association with B. afzelii. ACA presents months to years after initial infection with a poorly demarcated area of violaceous discoloration and swelling of involved skin. These lesions usually involve the extensor surfaces of the extremities including the dorsum of hands. Over time the lesions becomes atrophic, with a characteristic hyperpigmented, hairless, translucent appearance. Involvement of peripheral nerves is not uncommon causing sensory neuropathy in addition to cutaneous abnormalities. Lyme arthritis without neurologic symptoms can be treated with a 28-day oral regimen of either doxycycline 100 mg twice daily or amoxicillin 500 mg three times daily. Adults with evidence of concurrent neurologic involvement should receive intravenous ceftriaxone. Recurrent or persistent joint swelling after an oral regimen can be re-treated with another 28-day course of oral antimicrobials or with a two- to four-week parenteral regimen. Adults with late neurologic disease should be treated with a parenteral regimen for two to four weeks. Repeated or prolonged therapy is not recommended. Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window) Related Related posts: Cat scratch disease Hemangiomas Drug eruptions Erythropoietic protoporphyria Necrolytic migratory erythema Nevoid basal cell carcinoma syndrome Stay updated, free articles. Join our Telegram channel Join Tags: Treatment of Skin Disease Comprehensive Therapeutic Strategies Aug 7, 2016 | Posted by admin in Dermatology | Comments Off on Lyme borreliosis Full access? Get Clinical Tree
136 Lyme borreliosis David Banach and Gopi Patel Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports (Courtesy of Daniel Caplivski MD. Mount Sinai School of Medicine, New York, NY.) Lyme disease is a multisystem illness caused by spirochetes of the genus Borrelia. In North America, the causative agent is Borrelia burgdorferi. In Europe, borreliosis is caused primarily by B. afzelii followed by B. garni although other Borrelia species have been implicated. Clinical manifestations of Lyme disease depend on the stage of illness and may be limited to the skin or involve the nervous system, joints, or heart. Currently, Lyme disease is the most common vector-borne disease in the US. It is endemic in the northeast, the mid-Atlantic, and parts of Wisconsin and Minnesota. The most common vector for Lyme disease in the US is the Ixodes scapularis tick. I. pacificus has been linked to transmission of B. burgdorferi in the northwestern US. Mice and deer are the major reservoirs of B. burgdorferi. Ixodes ticks feed once in each of the three stages of their two-year life cycle. After hatching in the spring, larvae feed in summer, acquiring B. burgdorferi from their preferred host, the white-footed mouse. The following spring, the larvae develop into nymphs, which again feed off the white-footed mouse. The nymphs mature into adult ticks, which feed and mate in autumn and winter, usually on the white-tailed deer. B. burgdorferi is passed between ticks and their hosts. Humans can become accidental hosts during the spring and summer, when nymphs are actively feeding, through the deposition of organisms into the skin through tick saliva. Management strategy Routine antimicrobial prophylaxis or serologic testing after a tick bite is not recommended. Some experts recommend prophylaxis for patients bitten by I. scapularis ticks that have been attached over 36 hours if exposure occurred in an endemic area. This recommendation is based on evidence that a single 200 mg dose of doxycycline prevented 87% of Lyme infections if administered within 72 hours of tick removal. Accurate and detailed exposure history, however, is often unavailable. Those with a known tick exposure should be monitored for up to 30 days for the occurrence of skin lesions or fever. Cutaneous lesions or symptoms developing within one month after tick removal should prompt evaluation for early Lyme disease. The best mode of preventing Lyme disease is avoidance of tick-infested areas. If tick exposure is unavoidable, then one should wear light-colored clothing and long pants tucked into socks to prevent ticks from finding exposed skin. Skin self-inspection within 36 hours of tick exposure and bathing within 2 hours of exposure have been associated with decreased risk of Lyme borelliosis. Daily inspection of the entire body, including the scalp, is recommended since attached ticks removed within 24–36 hours are unlikely to transmit B. burgdorferi. DEET-containing insect repellents provide added protection. Ixodes ticks are small: larvae are less than 1 mm in size and adult females are 2–3 mm in size. Attached ticks should be removed with tweezers by carefully pulling on the mouth apparatus close to the skin, taking care not to leave parts of the embedded tick behind. Lyme disease generally occurs in stages, with different signs and symptoms at each stage. Therapeutic recommendations vary depending on the stage of disease and the presence of extracutaneous manifestations. Early localized Lyme disease The most common clinical manifestation of early Lyme disease is erythema migrans (EM). This characteristic skin lesion usually begins as an erythematous papule and develops into an expanding, erythematous, annular lesion with central clearing and distinct edge at the site of the tick bite and can be minimally tender. In most patients with Lyme, EM appears a median of 10 days after spirochete inoculation. The lesion may be accompanied by non-specific symptoms including fever, regional lymphadenopathy, arthralgias, fatigue, and headaches. About 75–80% of patients in the US who present with EM have a single primary lesion. Others can have secondary lesions due to hematogenous dissemination from the primary site. Untreated lesions usually fade within three to four weeks. Administration of doxycycline 100 mg twice daily, amoxicillin 500 mg three times daily, or cefuroxime axetil 500 mg twice daily for at least 14 days is recommended for early localized or early disseminated Lyme disease associated with EM. Doxycycline has the advantage of treating human granulocytic anaplasmosis caused by Anaplasma phagocytophilium, which also can be transmitted by I. scapularis. Doxycycline can cause photosensitivity and is contraindicated during pregnancy or breastfeeding and for children less than eight years old. A rare skin manifestation of early Lyme infection described predominantly in Europe is Borrelial Lymphocytoma (BL). This solitary bluish-red nodule occurs at the site of a tick bite typically preceding or concomitantly with EM. Commonly involved sites are the ear lobes in children and near or on the nipple in adults. BL may develop within weeks to months after a tick bite and if untreated can persist for months to years. Treatment regimens used to treat EM can be used to treat BL. Early disseminated Lyme disease Early dissemination of the spirochete occurs via blood or lymphatics over several weeks in untreated infection. In this setting multiple annular skin lesions resembling primary EM can appear though these lesions are generally smaller. Other common symptoms include fever, lethargy, myalgias, headache, and mild neck stiffness. Patients may present with atrioventricular (AV) conduction disturbances, iritis or uveitis, aseptic meningitis (lymphocytic pleocytosis in CSF), cranial nerve palsies (notably facial nerve palsies), or peripheral radiculopathy. In adults, intravenous ceftriaxone 2 g daily for 14–28 days is recommended for early Lyme disease presenting with neurologic or advanced cardiac conduction abnormalities. Parenteral penicillin or cefotaxime are second-line agents. Temporary pacing may be required for patients with high-degree AV block (PR interval ≥ 0.30 seconds). Insertion of a permanent pacer is not necessary as conduction defects resolve spontaneously. Isolated facial nerve palsy and first degree AV block can be treated with oral doxycycline. Late Lyme disease Late Lyme disease can occur months to years after previously untreated or inadequately treated initial infection. Lyme arthritis is the most common manifestation of late Lyme disease, although decreasing in incidence due to improved recognition of early disease. Lyme arthritis is oligoarticular and presents as recurrent swelling of large joints, primarily the knees. Persistent swelling is atypical. Positive serologic testing is required to confirm the diagnosis and positive PCR results from synovial fluid strengthens the diagnosis. Late neuroborreliosis is rare and can manifest as peripheral neuropathy, encephalomyelitis, or a subacute encephalopathy characterized by memory disturbances, mood alterations, and somnolence. A rare dermatologic finding associated with late Lyme disease is acrodermatitis chronica atrophicans (ACA). ACA has been predominantly described in elderly female patients and has rarely been seen in the US, but is not infrequent in Europe due to its association with B. afzelii. ACA presents months to years after initial infection with a poorly demarcated area of violaceous discoloration and swelling of involved skin. These lesions usually involve the extensor surfaces of the extremities including the dorsum of hands. Over time the lesions becomes atrophic, with a characteristic hyperpigmented, hairless, translucent appearance. Involvement of peripheral nerves is not uncommon causing sensory neuropathy in addition to cutaneous abnormalities. Lyme arthritis without neurologic symptoms can be treated with a 28-day oral regimen of either doxycycline 100 mg twice daily or amoxicillin 500 mg three times daily. Adults with evidence of concurrent neurologic involvement should receive intravenous ceftriaxone. Recurrent or persistent joint swelling after an oral regimen can be re-treated with another 28-day course of oral antimicrobials or with a two- to four-week parenteral regimen. Adults with late neurologic disease should be treated with a parenteral regimen for two to four weeks. Repeated or prolonged therapy is not recommended. Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window) Related Related posts: Cat scratch disease Hemangiomas Drug eruptions Erythropoietic protoporphyria Necrolytic migratory erythema Nevoid basal cell carcinoma syndrome Stay updated, free articles. Join our Telegram channel Join Tags: Treatment of Skin Disease Comprehensive Therapeutic Strategies Aug 7, 2016 | Posted by admin in Dermatology | Comments Off on Lyme borreliosis Full access? Get Clinical Tree
